k-ras mutation predictive significance in platinum based chemotherapeutic protocols in patients with advanced non-small cell lung cancer
Clicks: 254
ID: 250947
2009
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
254 views
35 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #100 of 134 articles by views in applied nursing research : anr
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 134 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Beckground/Aim. K-ras oncogene is mutated in about 20% of lung cancer. The purpose of this study was to investigate the predictive significance for therapeutic response of K-ras mutations in advanced non-small cell lung cancer (NSCLC) patients. Methods. Bronchial aspirate samples were assessed prior to platinum-based chemotherapy start in 39 patients with stage IIIb or IV NSCLC. K-ras mutations at codons 12 and 13 were analyzed by single strand conformation polymorphisam (SSCP) and allele specific oligonucleozide hybridisation of polymerase chain reaction (PCR) of the patient's DNA present in bronchial aspirate. After two cycles of chemotherapy the patients were subjected to response evaluation. Results. Of 39 patients 10 (25.5%) demonstrated K-ras mutations, while 29 (74.4%) patients had not. There were no significant differences between these two groups of patients with respect to baseline patient characteristics. Partial response to the therapy had 16 (41%), no changes 14 (36%), and progressive disease 9 (23%) patients. There was a tendency to higher response rate for patients without K-ras mutations versus those with mutations, but not statistically significant (p = 0.14). Conclusion. There was no significant predictive value for therapeutic response of K-ras mutations for advanced non-small cell lung cancer.
| Reference Key |
gordana2009vojnosanitetskik-ras
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Cvetković Gordana;Plavec Goran;Tomić Ilija;Ilić Vesna;Magić Zvonko;Tatomirović Željka;Novković Dobrivoje;Milić Rade;Karličić Vukojica |
| Journal | applied nursing research : anr |
| Year | 2009 |
| DOI |
10.2298/VSP0902149C
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.